Effects of dialysis purity on uremic dyslipidemia

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 1, 2010, Pages 5-11

  Schiffl, Helmut ^a,b   Lang, Susanne M ^b,c  

^a KfH Renal Center Munich Laim   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c SRH Wald Klinikum Gera   (Germany)

Author keywords

Maintenance dialysis; Ultrapure dialysis fluid; Uremic dyslipidemia

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DIALYSIS FLUID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; POLYSULFONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DIALYSATE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; LIPID ANALYSIS; MALE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRIACYLGLYCEROL BLOOD LEVEL; UREMIA; UREMIC DYSLIPIDEMIA;

AGED; C-REACTIVE PROTEIN; DYSLIPIDEMIAS; ENDOTOXINS; FEMALE; FOLLOW-UP STUDIES; HEMODIALYSIS SOLUTIONS; HUMANS; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OXIDATIVE STRESS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UREMIA;

EID: 77149156935     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2009.00713.x     Document Type: Article

References (25)

1. Collins AJ, Foley R, Herzog C, et al. Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis 2008 51 : S1 320.
2. Plantinga LC, Fink NE, Levin NW et al. Early, intermediate, and long-term risk factors for mortality in incident dialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. Am J Kidney Dis 2007 49 : 831 840.
3. Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol 2008 4 : 672 681.
4. Lonnemann G. When good water goes bad: how it happens, clinical consequences and possible solutions. Blood Purif 2004 22 : 124 129.
5. Schindler R. Inflammation and dialysate quality. Hemodial Int 2006 10 (Suppl. 1 S56 9.
6. Ibels LS, Stewart JH, Mahony JF, Neale FC, Sheil AG. Occlusive arterial disease in uraemic and haemodialysis patients and renal transplant recipients. A study of the incidence of arterial disease and of the prevalence of risk factors implicated in the pathogenesis of arteriosclerosis. Q J Med 1977 46 : 197 214.
7. Kronenberg F, Lingenhel A, Neyer U et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int Suppl 2003 S113 16.
8. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl 1997 62 : S53 5.
9. European Best Practice Guidelines for Haemodialysis (Part 1). Nephrol Dial Transplant 2002 17 (Suppl. 1 51 4.
10. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 353 : 238 248. (Pubitemid 41058323)
11. Panichi V, Paoletti S, Consani C. Inflammatory pattern in hemodiafiltration. Contrib Nephrol 2008 161 : 185 190.
12. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008 28 : 958 973.
13. Izuhara Y, Miyata T, Saito K. et al. Ultrapure dialysate decreases plasma pentosidine, a marker of "carbonyl stress". Am J Kidney Dis 2004 43 : 1024 1029.
14. Vaslaki L, Major L, Berta K et al. On-line haemodiafiltration versus haemodialysis: stable haematocrit with less erythropoietin and improvement of other relevant blood parameters. Blood Purif 2006 24 : 163 173.
15. Yavuz MT, Yavuz O, Yazici M et al. Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis. Scand J Clin Lab Invest 2006 66 : 523 534.
16. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and "lupus dyslipoproteinemia". Autoimmun Rev 2008 7 : 246 250.
17. Lundman P, Eriksson MJ, Silveira A et al. Relation of hypertriglyceridemia to plasma concentrations of biochemical markers of inflammation and endothelial activation (C-reactive protein, interleukin-6, soluble adhesion molecules, von Willebrand factor, and endothelin-1). Am J Cardiol 2003 91 : 1128 1131.
18. Khovidhunkit W, Kim MS, Memon RA et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004 45 : 1169 1196.
19. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004 19 : 2570 2575.
20. Himmelfarb J. Oxidative stress in hemodialysis. Contrib Nephrol 2008 161 : 132 137.
21. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005 9 : 37 46.
22. Yoon JW, Pahl MV, Vaziri ND. Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007 71 : 167 172.
23. Oka Y, Miyazaki M, Takatsu S et al. Lowering of oxidative stress in hemodialysis patients by dialysate cleaning: in relation to arteriosclerosis. Ther Apher Dial 2004 8 : 313 319.
24. Gerdemann A, Wagner Z, Solf A et al. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002 17 : 1045 1049.
25. Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005 23 : 311 316.